Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance.
Se Young ChoiBumjin LimYoon Soo KyungYunlim KimBong Min KimByung Hee JeonJae Chan ParkYoung Woong SohnJae Hyuk LeeJi-Hyun UhSeongsoo JangChoung-Soo KimPublished in: In vivo (Athens, Greece) (2020)
CTC counts in localized prostate cancer were associated with Gleason pattern 5. Active treatment should be considered for patients with low-risk disease during active surveillance who are found to have EpCAM+ CTCs because of a risk of up-staging and up-grading.